FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+19.09%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$2.5B
AUM Growth
+$2.5B
(+17%)
Cap. Flow
+$203M
Cap. Flow
% of AUM
8.14%
Top 10 Holdings %
Top 10 Hldgs %
59.89%
Holding
57
New
8
Increased
13
Reduced
5
Closed
4
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$155M |
| 2 |
Ascendis Pharma
ASND
|
$19.9M |
| 3 |
Alkermes
ALKS
|
$16.1M |
| 4 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$11.7M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$11.6M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$24M |
| 2 |
Vaxcyte
PCVX
|
$18.3M |
| 3 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$16.1M |
| 4 |
Applied Therapeutics
APLT
|
$10.7M |
| 5 |
PepGen
PEPG
|
$6.84M |
Sector Composition
| 1 | Healthcare | 99.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$3.71B
| $256M | 10.27% | 6,570,392 +75,000 | +1% | +$2.93M |
|
2
NewAmsterdam Pharma
NAMS
$2.71B
| $213M | 8.55% | 12,855,194 +628,251 | +5% | +$10.4M |
|
3
Phathom Pharmaceuticals
PHAT
$864M
| $183M | 7.33% | 10,109,279 | – | – |
|
4
Krystal Biotech
KRYS
$4.27B
| $180M | 7.21% | 988,460 | – | – |
|
|
MBX
5
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $155M | 6.23% | +5,985,347 | New | +$155M |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $127M | 5.08% | 2,416,952 +45,648 | +2% | +$2.39M |
|
|
7
Vaxcyte
PCVX
$4B
| $100M | 4.03% | 879,405 -160,000 | -15% | -$18.3M |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $97.4M | 3.9% | 3,383,950 +69,601 | +2% | +$2M |
|
9
BridgeBio Pharma
BBIO
$9.89B
| $95.7M | 3.84% | 3,760,457 +127,853 | +4% | +$3.26M |
|
10
Disc Medicine
IRON
$2.07B
| $86.2M | 3.46% | 1,754,834 | – | – |
|
11
Arcutis Biotherapeutics
ARQT
$1.86B
| $81.7M | 3.27% | 8,785,284 | – | – |
|
|
12
Edgewise Therapeutics
EWTX
$1.51B
| $75.6M | 3.03% | 2,832,867 -898,200 | -24% | -$24M |
|
13
AnaptysBio
ANAB
$569M
| $74M | 2.97% | 2,209,189 +43,598 | +2% | +$1.46M |
|
14
Erasca
ERAS
$445M
| $52.9M | 2.12% | 19,391,687 +3,175,471 | +20% | +$8.67M |
|
15
Tarsus Pharmaceuticals
TARS
$2.47B
| $52.2M | 2.09% | 1,587,527 | – | – |
|
16
Agios Pharmaceuticals
AGIO
$2.19B
| $46.4M | 1.86% | 1,044,154 +172,180 | +20% | +$7.65M |
|
17
Revolution Medicines
RVMD
$7.1B
| $45.2M | 1.81% | 997,455 | – | – |
|
18
Soleno Therapeutics
SLNO
$3.6B
| $44.2M | 1.77% | 875,667 | – | – |
|
19
KalVista Pharmaceuticals
KALV
$678M
| $42.7M | 1.71% | 3,687,867 | – | – |
|
20
Oric Pharmaceuticals
ORIC
$994M
| $42.5M | 1.7% | 4,142,855 | – | – |
|
|
21
Ultragenyx Pharmaceutical
RARE
$2.89B
| $35.2M | 1.41% | 633,715 +208,715 | +49% | +$11.6M |
|
22
Savara
SVRA
$567M
| $34.6M | 1.39% | 8,157,385 | – | – |
|
23
CG Oncology
CGON
$2.04B
| $29.1M | 1.16% | 770,000 | – | – |
|
24
Rocket Pharmaceuticals
RCKT
$354M
| $27.4M | 1.1% | 1,485,630 -75,600 | -5% | -$1.4M |
|
25
Trevi Therapeutics
TRVI
$883M
| $24.7M | 0.99% | 7,381,090 | – | – |
|